This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
by Zacks Equity Research
Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.
Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of 46.34% and 7.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Dicerna Pharmaceuticals (DRNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -203.92% and -68.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Dicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 20th
by Zacks Equity Research
AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.
New Strong Sell Stocks for July 15th
by Zacks Equity Research
ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -39.29% and -20.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Dicerna (DRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Dicerna (DRNA) stock based on the movements in the options market lately.
Will Dicerna Pharmaceuticals (DRNA) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -304.76% and -46.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Dicerna Pharmaceuticals (DRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -210.71% and -42.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -625.00% and -73.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.
Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1%
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Dicerna Pharmaceuticals (DRNA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -72.73% and -70.67%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -26.09% and -81.60%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -45.83% and -7.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
by Zacks Equity Research
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Dicerna Pharmaceuticals (DRNA) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of 33.33% and -13.69%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?
by Zacks Equity Research
On ACADIA's (ACAD) second-quarter 2018 conference call, investor focus will be on the sales figures of its only marketed drug Nuplazid as well as its pipeline progress.